中国医药
(600056)
| 流通市值：158.21亿 | | | 总市值：158.26亿 |
| 流通股本：14.95亿 | | | 总股本：14.96亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 26,099,729,998.4 | 17,797,322,228.73 | 8,774,845,924.57 | 38,824,430,504.85 |
| 营业收入 | 26,099,729,998.4 | 17,797,322,228.73 | 8,774,845,924.57 | 38,824,430,504.85 |
| 二、营业总成本 | 25,216,783,611.99 | 17,153,291,092.83 | 8,513,876,388.41 | 37,501,895,075.86 |
| 营业成本 | 23,317,058,605.89 | 15,856,033,265.53 | 7,871,334,132.38 | 34,440,813,684.04 |
| 税金及附加 | 68,753,867.61 | 45,944,436.93 | 22,941,223.84 | 127,402,543.62 |
| 销售费用 | 836,164,693.31 | 589,386,726.56 | 302,649,355.63 | 1,610,899,512.87 |
| 管理费用 | 777,491,393.59 | 509,539,878.02 | 240,790,306.97 | 1,095,203,837.11 |
| 研发费用 | 89,752,947.32 | 63,682,744.87 | 32,492,507.73 | 115,537,321.14 |
| 财务费用 | 127,562,104.27 | 88,704,040.92 | 43,668,861.86 | 112,038,177.08 |
| 其中:利息费用 | 113,574,940.63 | 87,148,230.11 | 38,341,753.73 | 204,277,179.29 |
| 其中:利息收入 | 47,774,014.36 | 22,286,494.14 | 14,692,808.48 | 46,353,756.63 |
| 加:公允价值变动收益 | -1,108,515.03 | -1,108,515.03 | -443,067.53 | 984,924.25 |
| 加:投资收益 | 5,002,730.82 | 1,310,642.23 | 3,651,674.19 | -15,792,210.92 |
| 资产处置收益 | 1,026,006.48 | -102,314.12 | -31,273.74 | 437,488,523.22 |
| 资产减值损失(新) | 1,150,416.96 | 1,216,930.7 | -56,686.55 | -13,539,284.7 |
| 信用减值损失(新) | -65,698,071.63 | -56,918,894.18 | 3,508,443.45 | -143,845,175.08 |
| 其他收益 | 27,245,720.58 | 18,223,735.46 | 7,933,623.95 | 84,502,016.89 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 850,564,674.59 | 606,652,720.96 | 275,532,249.93 | 1,672,334,222.65 |
| 加:营业外收入 | 9,766,439.48 | 6,718,433.17 | 923,335.24 | 25,418,798.57 |
| 减:营业外支出 | 17,547,335.07 | 9,347,320.68 | 2,889,437.23 | 57,197,500.42 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 842,783,779 | 604,023,833.45 | 273,566,147.94 | 1,640,555,520.8 |
| 减:所得税费用 | 221,865,802.33 | 154,267,062.99 | 70,685,327.66 | 398,435,055.84 |
| 六、净利润 | 620,917,976.67 | 449,756,770.46 | 202,880,820.28 | 1,242,120,464.96 |
| 持续经营净利润 | 620,917,976.67 | 449,756,770.46 | 202,880,820.28 | 1,242,120,464.96 |
| 归属于母公司股东的净利润 | 447,148,326.32 | 325,119,038.69 | 145,599,951.99 | 1,048,039,144.39 |
| 少数股东损益 | 173,769,650.35 | 124,637,731.77 | 57,280,868.29 | 194,081,320.57 |
| (一)基本每股收益 | 0.3 | 0.22 | 0.1 | 0.7 |
| (二)稀释每股收益 | 0.3 | 0.22 | 0.1 | 0.7 |
| 八、其他综合收益 | -3,545,260.38 | -1,457,158.88 | 1,361,482.42 | -40,686,616.87 |
| 归属于母公司股东的其他综合收益 | -3,545,260.38 | -1,457,158.88 | 1,361,482.42 | -40,700,088.42 |
| 九、综合收益总额 | 617,372,716.29 | 448,299,611.58 | 204,242,302.7 | 1,201,433,848.09 |
| 归属于母公司股东的综合收益总额 | 443,603,065.94 | 323,661,879.81 | 146,961,434.41 | 1,007,339,055.97 |
| 归属于少数股东的综合收益总额 | 173,769,650.35 | 124,637,731.77 | 57,280,868.29 | 194,094,792.12 |
| 公告日期 | 2024-10-26 | 2024-08-21 | 2024-04-30 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |